ACS in perspective: The importance of secondary prevention

Deloitte Access Economics

Research output: Book/ReportCommissioned report

Abstract

Deloitte Access Economics was commissioned by AstraZeneca Australia to estimate the economic cost of acute coronary syndrome (ACS) and to explore the extent of investment in secondary prevention of ACS.
Original languageEnglish
Place of PublicationSydney
PublisherDeloitte
Commissioning bodyAstraZeneca Australia
Number of pages83
Publication statusPublished - 2011
Externally publishedYes

Fingerprint Dive into the research topics of 'ACS in perspective: The importance of secondary prevention'. Together they form a unique fingerprint.

Cite this